Our Banking and Finance department represented Kamada, a leading Israeli biopharmaceutical company (dual listed on TASE and NASDAQ), in a strategic financing transaction, to finance the purchase of a plasma-based and FDA approved portfolio from American pharmaceutical company Saol Therapeutics, for the sum of $110 Million.
Partner Yona Goshen Gottstein, and associates itamar shimonovitz and Gili Bartura had represented Kamada on this deal.
Click here to read more about this transaction.